Holen Sie sich die Stockscreener-App
103.67
1.89%
-2.00
Handel nachbörslich:
104.49
0.82
+0.79%
Schlusskurs vom Vortag:
$105.67
Offen:
$105.41
24-Stunden-Volumen:
874.04K
Relative Volume:
1.07
Marktkapitalisierung:
$5.46B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-15.88
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-6.49%
1M Leistung:
+0.14%
6M Leistung:
+6.47%
1J Leistung:
+34.04%
1-Tages-Spanne:
$103.02
$106.84
1-Wochen-Bereich:
$103.02
$112.25
52-Wochen-Spanne:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
103.67 | 5.46B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Globe and Mail
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Motley Fool
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Is Axsome Therapeutics Stock Worth The Risk? A Comprehensive Analysis - Barchart.com
Fibromyalgia Treatment Market to Reach $3.88 Billion by 2033 | - openPR.com
Axsome in $570 million loan and revolving credit facility with Blackstone - The Pharma Letter
Frontier Capital Management Co. LLC Has $4.47 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q2 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
Transcript : Axsome Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
William Blair Analysts Boost Earnings Estimates for AXSM - MarketBeat
Cubist Systematic Strategies LLC Invests $9.89 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Fairmount Funds Management LLC Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Major Depressive Disorder Market Growth to Accelerate - openPR.com
Axsome Therapeutics enters $570M term loan, credit facility with Blackstone - MSN
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Axsome Therapeutics Enters $570 Million Credit Deal With Blackstone - marketscreener.com
Axsome Therapeutics (AXSM) Secures $570 Million Credit Facility - GuruFocus
Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - Nasdaq
Axsome Therapeutics Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - marketscreener.com
3 Monster Stocks in the Making - aol.com
Axsome secures $570 million credit facility from Blackstone - Investing.com
Axsome secures $570 million credit facility from Blackstone By Investing.com - Investing.com Nigeria
Axsome Therapeutics Secures $570 Million Financing Facility with Blackstone, Retires Previous Loan - Nasdaq
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - The Manila Times
BNP Paribas Financial Markets Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Northern Trust Corp - MarketBeat
HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat
Price T Rowe Associates Inc. MD Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Has Bullish Forecast for AXSM FY2028 Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC Wainwright - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Schonfeld Strategic Advisors LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $162.00 Price Target at Robert W. Baird - MarketBeat
Balyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% Following Better-Than-Expected Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Quarterly Earnings Results, Beats Estimates By $0.46 EPS - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
BVF Inc. IL Has $117.44 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2025 EPS Estimates for AXSM Lifted by Cantor Fitzgerald - MarketBeat
Axsome Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Alethea Capital Management LLC Has $62.13 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 14.2% in April - MarketBeat
Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 - MSN
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - Yahoo Finance
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):